Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study
In the meantime, the availability of the two highest-dose Zepbound vials gives providers and patients another important treatment option. Patients with obesity who choose to self pay will soon be able to access the complete range of Zepbound single-dose vials, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
Retatrutide remains under clinical investigation and has not yet received regulatory approval, with ongoing Phase 3 trials evaluating long-term safety and effectiveness
Skin folding and creasing become more apparent on the underside of the buttocks
Patients often choose this infusion for skin brightness, faster recovery, and immune boost